Equities research analysts expect Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) to post earnings per share of ($0.34) for the current quarter, according to Zacks. Zero analysts have issued estimates for Magenta Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.37). Magenta Therapeutics posted earnings of ($0.36) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 5.6%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Magenta Therapeutics will report full year earnings of ($1.43) per share for the current year, with EPS estimates ranging from ($1.55) to ($1.30). For the next year, analysts expect that the business will post earnings of ($1.45) per share, with EPS estimates ranging from ($1.65) to ($1.18). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Magenta Therapeutics.
Magenta Therapeutics (NASDAQ:MGTA – Get Rating) last announced its quarterly earnings results on Tuesday, March 8th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.01).
Large investors have recently bought and sold shares of the stock. Morgan Stanley increased its stake in Magenta Therapeutics by 6,706.4% during the second quarter. Morgan Stanley now owns 59,352 shares of the company’s stock valued at $581,000 after acquiring an additional 58,480 shares during the period. Millennium Management LLC lifted its holdings in shares of Magenta Therapeutics by 47.9% during the 2nd quarter. Millennium Management LLC now owns 64,115 shares of the company’s stock worth $627,000 after acquiring an additional 20,765 shares during the period. Invesco Ltd. acquired a new stake in shares of Magenta Therapeutics during the 2nd quarter valued at about $107,000. Vontobel Holding Ltd. bought a new stake in Magenta Therapeutics in the third quarter valued at about $108,000. Finally, SG Americas Securities LLC acquired a new position in Magenta Therapeutics in the third quarter worth about $107,000. Institutional investors and hedge funds own 59.13% of the company’s stock.
MGTA stock traded down $0.09 on Friday, reaching $1.59. The company’s stock had a trading volume of 290,892 shares, compared to its average volume of 141,661. Magenta Therapeutics has a 12-month low of $1.55 and a 12-month high of $13.22. The firm has a market cap of $93.49 million, a PE ratio of -1.21 and a beta of 2.01. The business has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $4.53.
Magenta Therapeutics Company Profile (Get Rating)
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants.
- Get a free copy of the StockNews.com research report on Magenta Therapeutics (MGTA)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.